Xalkori (crizotinib)

This first documented case demonstrates the therapeutic efficacy of crizotinib in ALK-IR rearranged NSCLC, emphasizing the importance of comprehensive molecular profiling in guiding precision oncology.

The patient was treated with the oral targeted drug crizotinib and died of multiple organ failure 18 months after surgery...UIMT and EIMS that exhibit aggressive behavior typically possess a greater number of genetic alterations. The abnormal expression of p53 or p16 protein, when combined with clinicopathological parameters, can serve as indicators for predicting the adverse biological behavior of tumors.

Despite robust evidence supporting ALK-targeted therapies, this study highlights substantial disparities in access to diagnostics and treatment for ALK-rearranged NSCLC in Brazil, particularly among patients reliant on the public health care system. Findings underscore the need for policies to strengthen testing infrastructure, ensure equitable access to guideline-recommended therapies, and enhance provider education. Addressing these gaps is essential for equitable precision oncology and improved outcomes.

Upon light irradiation, the caged compound undergoes efficient uncaging to release active Crizotinib, restoring its potent kinase inhibitory and antiproliferative activities. This work establishes BODIPY-caged Crizotinib as a promising photoactivatable agent for precision cancer therapy.

During treatment, reducing crizotinib dosage does not lead to recurrence of lung cancer while minimizing complications. The case underscores the necessity of integrating imaging and pathological features in the diagnostic process, alongside the need for personalized adjustments and development of treatment plans tailored to each patient.

With median PFS yet to be reached after 7 years of follow-up in CROWN, lorlatinib continues to show unprecedented long-term benefit in patients with advanced ALK-positive NSCLC. Patients without progression within 24 months on lorlatinib have a low risk of progression or death at year 7 and may continue long-term treatment. Findings suggest that sustained long-term disease control with first-line lorlatinib may enable advanced ALK-positive NSCLC to evolve toward a chronic condition.

This exploratory study identified WDR17 as a candidate biomarker associated with TKI resistance in lung adenocarcinoma, potentially involved in maintaining protein homeostasis and metabolic balance. These preliminary findings warrant validation in larger, independent cohorts.

P2, N=534, Active, not recruiting, Hoffmann-La Roche | Trial completion date: May 2026 --> Jun 2027 | Trial primary completion date: May 2026 --> Jun 2027

While vebreltinib appears clinically advantageous over crizotinib for METex14-mutated NSCLC, the therapeutic benefits did not reach statistical significance in this study. The observed differential response patterns and resistance mechanisms suggest distinct biological behaviors to type Ia and Ib MET TKIs that warrant further investigation. These findings underscore the need for larger prospective studies to validate the potential superiority of vebreltinib and to better characterize the molecular determinants in NSCLC.

Molecular docking simulations suggested promising drug repurposing avenues, particularly with afatinib and crizotinib, for GABRD inhibition. GABRD gene may serve as a novel biomarker in the diagnosis, prognosis and immune infiltrates of CRC patients.

Furthermore, patients in the low-risk group may demonstrate greater sensitivity to crizotinib while exhibiting reduced responsiveness to gefitinib. Two robust molecular subtypes of LUAD were identified through consensus clustering. By constructing prognostic models centered on APRGs, this investigation systematically elucidated the immune microenvironment and molecular underpinnings of LUAD, contributing fresh perspectives on disease mechanisms and potential treatment avenues.

Subsequently, the patient received furmonertinib targeted therapy. Herein, we discuss the diagnostic challenges and the potential pathogenic mechanisms of this novel mutation. How to identify rare genes and translate their identification into clinical benefits is a worthwhile avenue for exploration in our future work.